Myeloma Video Channel
Explore the latest insights and summaries from experts in Myeloma.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
University of Colorado Division of Hematology
Multiple Myeloma: Initial Treatment Approaches
FEATURING
Alex Hirose
- 69 views
- October 22, 2024
- 2
Cleveland Clinic Taussig Cancer Institute
Updates in Plasma Cell Disorders From ASH 2023
FEATURING
Jack Khouri
- 17 views
- October 22, 2024
University of Colorado Division of Hematology
The Future of Multiple Myeloma: SCT, CAR-T, and BiTE Therapy
FEATURING
Kelly Sidor
- 78 views
- October 23, 2024
- 1
Dana-Farber Cancer Institute
FDA Approval of Isatuximab in 1L MM: Perspectives for Practice
FEATURING
Paul Richardson
- 550 views
- November 12, 2024
- 7
Yale Cancer Center
Multiple Myeloma: Hot Topics in 2024
FEATURING
Sabrina Browning
- 193 views
- October 21, 2024
- 3
Springer Healthcare IME
Anti-BCMA ADCs - Independent Symposium at the 10th World Congress on Controversies in Multiple Myeloma (COMy)
FEATURING
Rakesh Popat
- 60 views
- October 30, 2024
- 1
Saurabh Chhabra
Len/Dara vs. Len Maintenance in NDMM: Comparing DRAMMATIC, PERSEUS, and AURIGA Ph3 Studies
- 87 views
- November 3, 2024
- 1
MyCancerHaven
Experts Discuss How They Sequence MM Therapies
FEATURING
Ravi Vij,
Rachid Baz
- 103 views
- May 24, 2024
Moffitt Cancer Center
CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real World
FEATURING
Doris Hansen
- 245 views
- May 24, 2024
- 1
Dana-Farber Cancer Institute
Continued Evolution of Therapy for Patients With Newly Diagnosed MM
FEATURING
Clifton Mo
- 144 views
- June 10, 2024
- 2
Memorial Sloan Kettering Cancer Center
ASTCT Survey on Management of R/R Myeloma Patients After Failure by CAR-T
FEATURING
Hamza Hashmi
- 142 views
- May 21, 2024
- 1
MyCancerHaven
Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?
FEATURING
Ravi Vij,
Samer Al Hadidi
- 625 views
- May 23, 2024
- 5
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"
FEATURING
Ola Landgren
- 417 views
- June 12, 2024
- 7
ecancer
ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"
FEATURING
Xavier Leleu
- 187 views
- June 24, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"
FEATURING
Samir Parekh
- 245 views
- June 25, 2024
- 4
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 474 views
- June 27, 2024
- 7
Rush University Medical Center
High-Risk Myeloma: Updates in Defining and Managing
FEATURING
Jeffrey Zonder
- 133 views
- June 6, 2024
Rush University Medical Center
CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Directions
FEATURING
Attaya Suvannasankha
- 197 views
- June 14, 2024
- 2
Rush University Medical Center
The Role of SCT Amidst Emerging Therapies in the Treatment of AL Amyloidosis
FEATURING
Vaishali Sanchorawala
- 37 views
- June 14, 2024
- 1
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 650 views
- July 1, 2024
- 5
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstracts"
FEATURING
Hamza Hashmi
- 625 views
- July 1, 2024
- 5
Integrity CE
Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy
FEATURING
Saad Usmani,
Jens Hillengass
- 218 views
- August 13, 2024
- 2
SOHO Brazil 2024
Frontline MM: Are Four Better Than Three?
FEATURING
Noopur S. Raje
- 79 views
- July 11, 2024
- 1
SOHO Brazil 2024
When to Consider Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 411 views
- July 11, 2024
- 5
ecancer
EHA 2024 Summary: Highlights of Key Studies in Multiple Myeloma
FEATURING
Claudio Cerchione
- 112 views
- July 23, 2024
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment
FEATURING
Andrzej Jakubowiak
- 260 views
- July 31, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment
FEATURING
Andrzej Jakubowiak
- 310 views
- July 31, 2024
- 3
UCSF School of Medicine
Best of ASCO® 2024: Myeloma Highlights and Practice Impacts
FEATURING
Ajai Chari
- 183 views
- August 7, 2024
- 2
Integrity CE
Current Updates in the Management of NDMM
FEATURING
Jens Hillengass,
Saad Usmani
- 82 views
- August 15, 2024
MyCancerHaven
DreaMM-7 and DreaMM-8: Ready for the Return of Belamaf in Myeloma?
FEATURING
Ravi Vij,
Ajai Chari
- 129 views
- September 3, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: Myeloma
FEATURING
Jennifer Cooperrider
- 87 views
- September 4, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Sequencing Immunotherapies and CAR-T Application in Multiple Myeloma
FEATURING
Claudio Cerchione
- 38 views
- September 6, 2024
UNC Lineberger Comprehensive Cancer Center
Updates on the Management of Later Relapses of Multiple Myeloma
FEATURING
Samuel Rubinstein
- 80 views
- September 16, 2024
UNC Lineberger Comprehensive Cancer Center
Updates on the Management of Early Relapsed Multiple Myeloma
FEATURING
Samuel Rubinstein
- 45 views
- September 16, 2024
UNC Lineberger Comprehensive Cancer Center
Updates on the Management of 1L Multiple Myeloma
FEATURING
Samuel Rubinstein
- 79 views
- September 16, 2024
- 1
Dana-Farber Cancer Institute
Updates on AL Amyloidosis Treatment: What’s New in 2024
FEATURING
Giada Bianchi
- 180 views
- July 2, 2024
Meral Beksaç
Post ASCO®/EHA 2024 Treatment of Transplant Ineligible Myeloma Patients
- 39 views
- July 22, 2024
Nebraska Oncology Society
Updates on Advances in the Treatment R/R Myeloma
FEATURING
Ravi Vij
- 78 views
- August 1, 2024
Nebraska Oncology Society
Updates on Advances in the Treatment of Newly Diagnosed Myeloma
FEATURING
Ravi Vij
- 88 views
- August 1, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Treatment of 1L Myeloma in 2024
FEATURING
Ahmad Ibrahim
- 34 views
- August 26, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Comprehensive Review of 1L Therapy Approaches in MM
FEATURING
Alpay Yeşilaltay
- 11 views
- August 26, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Treatment Strategies for R/R Multiple Myeloma
FEATURING
Claudio Cerchione
- 30 views
- September 6, 2024
Houston Methodist
Multiple Myeloma: A Journey From Pharaoh's Times to 2024
FEATURING
Siddhartha Ganguly
- 179 views
- September 10, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 467 views
- September 23, 2024
- 2
COR2ED The Heart of Medical Education
Current Best Practices in Treating Early R/R MM
FEATURING
Joseph Mikhael
- 14 views
- October 1, 2024
COR2ED The Heart of Medical Education
Unmet Medical Needs in Early MM Relapse
FEATURING
Elena Zamagni
- 27 views
- October 1, 2024
Fredrik Schjesvold
Decision Making Post-ASCT in Myeloma - Data Supporting Strategies
- 13 views
- October 8, 2024
Scripps Health
AL Amyloidosis: Current and Emerging Treatments
FEATURING
David Oveisi
- 11 views
- November 4, 2024
Indy Hematology Review
Multiple Myeloma: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 230 views
- April 18, 2024
- 2
Indy Hematology Review
Managing Amyloidosis in 2024: Diagnosis and Treatment
FEATURING
Morie Gertz
- 968 views
- April 23, 2024
- 8
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 243 views
- April 30, 2024
- 2
Oncology Data Advisor
Multiple Myeloma Awareness Month: What Patients Need to Know
- 17 views
- May 6, 2024
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
FEATURING
Daniel Sherbenou
- 436 views
- April 11, 2024
- 1
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
- 383 views
- April 19, 2024
- 2
MyCancerHaven
Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and Bispecifics
FEATURING
Ravi Vij,
Nitya Nathwani
- 261 views
- May 2, 2024
- 2
Memorial Sloan Kettering Cancer Center
Key Myeloma & MGUS Updates From ASH
FEATURING
Sham Mailankody
- 327 views
- May 2, 2024
- 2
Indy Hematology Review
Managing Newly Diagnosed MM in 2024
FEATURING
Saad Usmani
- 691 views
- May 2, 2024
- 5
MyCancerHaven
Treating Amyloidosis in 2024
FEATURING
Ravi Vij,
Jeffrey Zonder
- 162 views
- May 9, 2024
- 1
MyCancerHaven
The Influence of PERSEUS and IsKia Trials on Frontline Therapy Choices in MM
FEATURING
Ravi Vij,
Thomas Martin
- 91 views
- May 13, 2024
- 2
Yale Cancer Center
Frontline Treatment Strategies in MM: A Comprehensive Overview of Clinical Trials and Real-World Data
FEATURING
Terri Parker
- 118 views
- May 14, 2024
- 1
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of CAR-Ts in Earlier Lines
FEATURING
Doris Hansen
- 378 views
- April 15, 2024
- 2
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
FEATURING
Kenneth Anderson
- 1,224 views
- April 16, 2024
- 5
City of Hope
Sequencing T-Cell Therapies in Relapsed Myeloma: BCMA, Bispecifics, and Resistance
FEATURING
Amrita Krishnan
- 56 views
- November 21, 2024
Winship Cancer Institute - Emory University
Triplets vs. Quadruplets: What Is the Right Approach for NDMM?
FEATURING
Nisha Joseph
- 32 views
- November 25, 2024
Total Health
Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist
FEATURING
Sarah Medeiros
- 126 views
- November 26, 2024
- 2
COR2ED The Heart of Medical Education
The Relevance of Adding a New Mechanism of Action in R/R MM
FEATURING
Fredrik Schjesvold
- 12 views
- October 1, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in MM: The Role of Immunotherapy
FEATURING
Adam D. Cohen
- 291 views
- March 1, 2024
- 4
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dyscrasias
- 117 views
- March 6, 2024
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should NOT Use a Response-Adapted Approach to Transplant
FEATURING
Omar Castañeda-Puglianini
- 192 views
- March 11, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Managing Newly Diagnosed Myeloma in 2024
FEATURING
Alfred Garfall
- 428 views
- March 11, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Approaches to Preventing and Treating GVHD in 2024
FEATURING
Nasheed Hossain
- 137 views
- March 11, 2024
- 2
GRACE
Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussion
- 133 views
- March 15, 2024
UChicago Medicine
Multiple Myeloma: CAR T-Cells and Bispecifics - A Case for Moving Them Early
FEATURING
Noopur Raje
- 257 views
- March 18, 2024
- 1
UChicago Medicine
Practice-Changing and Promising New Treatments in Myeloma
FEATURING
Ben Derman
- 135 views
- March 19, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Multiple Myeloma
FEATURING
Sagar Lonial
- 307 views
- March 25, 2024
Scripps Health
Should Patients With High-Risk SMM Be Treated Outside a Clinical Trial? No
FEATURING
Morie Gertz
- 528 views
- March 29, 2024
- 5
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent FDA ODAC Meeting
- 606 views
- March 29, 2024
- 3
Shaji Kumar
Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patients
- 87 views
- December 10, 2024
- 3
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L ASCT - KarMMa-2 Trial Follow-Up
FEATURING
Barry Paul
- 3 views
- December 17, 2024
Therapeutic Agents
Cleveland Clinic Taussig Cancer Institute
Updates in Plasma Cell Disorders From ASH 2023
FEATURING
Jack Khouri
- 17 views
- October 22, 2024
University of Colorado Division of Hematology
The Future of Multiple Myeloma: SCT, CAR-T, and BiTE Therapy
FEATURING
Kelly Sidor
- 78 views
- October 23, 2024
- 1
ecancer
Frailty Subanalysis of IMROZ: Isatuximab + RVD for Transplant-Ineligible NDMM Patients
FEATURING
Salomon Manier
- 11 views
- November 12, 2024
Dana-Farber Cancer Institute
FDA Approval of Isatuximab in 1L MM: Perspectives for Practice
FEATURING
Paul Richardson
- 550 views
- November 12, 2024
- 7
Yale Cancer Center
Multiple Myeloma: Hot Topics in 2024
FEATURING
Sabrina Browning
- 193 views
- October 21, 2024
- 3
Meletios Dimopoulos
D-VRd With D-R Maintenance in Transplant-Eligible NDMM: PERSEUS Cytogenetic Risk Analysis
- 104 views
- October 21, 2024
- 1
Icahn School of Medicine at Mount Sinai
CAR-T in MM: Best Practices in Patient Selection, Treatment, and Multidisciplinary Care
FEATURING
Adriana Rossi
- 73 views
- November 10, 2024
Joseph Mikhael
The Relapsed and Refractory MM Patient: When Immune Approaches Are Ineffective
- 100 views
- November 10, 2024
- 2
Springer Healthcare IME
Anti-BCMA ADCs - Independent Symposium at the 10th World Congress on Controversies in Multiple Myeloma (COMy)
FEATURING
Rakesh Popat
- 60 views
- October 30, 2024
- 1
Springer Healthcare IME
Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th World Congress on Controversies in Multiple Myeloma (COMy)
FEATURING
Saad Usmani
- 184 views
- October 30, 2024
- 2
Meera Mohan
Evaluating Infection Risk in CAR T-Cell Therapy and Bispecific Antibodies for Myeloma
- 57 views
- November 13, 2024
MyCancerHaven
Experts Discuss How They Sequence MM Therapies
FEATURING
Ravi Vij,
Rachid Baz
- 103 views
- May 24, 2024
Moffitt Cancer Center
CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real World
FEATURING
Doris Hansen
- 245 views
- May 24, 2024
- 1
Dana-Farber Cancer Institute
Continued Evolution of Therapy for Patients With Newly Diagnosed MM
FEATURING
Clifton Mo
- 144 views
- June 10, 2024
- 2
Saurabh Chhabra
BCMA-Directed Bispecifics in MM: Clinical Data & Guidelines for AE Management
- 147 views
- May 21, 2024
- 1
MyCancerHaven
Incorporating Selinexor Into the Myeloma Practice
FEATURING
Ravi Vij,
Cristina Gasparetto
- 89 views
- May 22, 2024
MyCancerHaven
Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?
FEATURING
Ravi Vij,
Samer Al Hadidi
- 625 views
- May 23, 2024
- 5
MyCancerHaven
Experts Discuss CELMoDs in MM: Current Data and Future Applications
- 91 views
- May 23, 2024
- 1
Dana-Farber Cancer Institute
Future of Novel Next Generation Therapy in the Management of R/R MM
FEATURING
Paul Richardson
- 221 views
- June 18, 2024
- 3
ecancer
ASCO® 2024 Insights: "IMROZ - A Ph3 Study of Isatuximab + VRd vs. VRd for Transplant-Ineligible NDMM"
FEATURING
Thierry Facon
- 109 views
- June 24, 2024
ecancer
ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"
FEATURING
Xavier Leleu
- 187 views
- June 24, 2024
- 1
ecancer
ASCO® 2024 Insights: "Results of Preliminary Safety & Efficacy of Belantamab Mafodotin and Elotuzumab in R/R MM"
FEATURING
Natalia Neparidze
- 73 views
- June 25, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"
FEATURING
Samir Parekh
- 245 views
- June 25, 2024
- 4
Yale Cancer Center
Advances in CAR-Ts in Myeloma: Recent Research & Clinical Findings
FEATURING
Noffar Bar
- 110 views
- May 20, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 97 views
- June 20, 2024
James Essell
Bringing CAR-T for Hematologic Malignancies to the Community Practices
- 59 views
- June 20, 2024
ecancer
ASCO® 2024 Insights: "Long-Term Follow-Up of MajesTEC-1 Trial - Teclistamab in R/R MM"
FEATURING
Alfred Garfall
- 28 views
- June 20, 2024
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 474 views
- June 27, 2024
- 7
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "DREAMM-7 Trial - BelamafVd vs. DaraVd in R/R MM"
FEATURING
Maria-Victoria Mateos
- 288 views
- June 6, 2024
- 1
Rush University Medical Center
CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Directions
FEATURING
Attaya Suvannasankha
- 197 views
- June 14, 2024
- 2
Rush University Medical Center
BCMA & Beyond: Novel Targets for Immunotherapy in MM
FEATURING
Ben Derman
- 160 views
- June 14, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Current Status of Bispecific Antibody Therapy in R/R MM"
FEATURING
Meera Mohan
- 158 views
- June 16, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The BENEFIT Study - Isa-VRd vs. Isa-Rd for Transplant-Ineligible NDMM"
FEATURING
Xavier Leleu
- 155 views
- June 11, 2024
ecancer
ASCO® 2024 Insights: "MajesTEC-7 Study - Safety and Efficacy of Tec-DR in NDMM"
FEATURING
Salomon Manier
- 67 views
- June 26, 2024
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 650 views
- July 1, 2024
- 5
Dana-Farber Cancer Institute
Bispecific Antibody Therapy in Multiple Myeloma
FEATURING
Shonali Midha
- 60 views
- July 1, 2024
Dana-Farber Cancer Institute
[PRIVATE] Bispecific Antibody Therapy in Multiple Myeloma
FEATURING
Shonali Midha
- July 1, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstracts"
FEATURING
Hamza Hashmi
- 625 views
- July 1, 2024
- 5
Supratik Basu
How I Approach Switching to Daratumumab SC From IV in Patients With MM
- 119 views
- August 2, 2024
- 2
SOHO Brazil 2024
When to Consider Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 411 views
- July 11, 2024
- 5
SOHO Brazil 2024
Managing Infectious Complications With Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 193 views
- July 11, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment
FEATURING
Andrzej Jakubowiak
- 260 views
- July 31, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Status of Lenalidomide Maintenance in Myeloma
FEATURING
Ant Uzay
- 16 views
- August 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Overview of Biscpecific Antibodies in Hematologic Malignancies
FEATURING
Bahar Uncu Ulu
- 50 views
- August 15, 2024
MyCancerHaven
DreaMM-7 and DreaMM-8: Ready for the Return of Belamaf in Myeloma?
FEATURING
Ravi Vij,
Ajai Chari
- 129 views
- September 3, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: Myeloma
FEATURING
Jennifer Cooperrider
- 87 views
- September 4, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Sequencing Immunotherapies and CAR-T Application in Multiple Myeloma
FEATURING
Claudio Cerchione
- 38 views
- September 6, 2024
GRACE
Emerging Treatment Options for AL Amyloidosis
FEATURING
Sridevi Rajeeve
- 31 views
- September 16, 2024
UNC Lineberger Comprehensive Cancer Center
Updates on the Management of Later Relapses of Multiple Myeloma
FEATURING
Samuel Rubinstein
- 80 views
- September 16, 2024
UNC Lineberger Comprehensive Cancer Center
Updates on the Management of Early Relapsed Multiple Myeloma
FEATURING
Samuel Rubinstein
- 45 views
- September 16, 2024
Maria-Victoria Mateos
CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Multiple Myeloma
- 215 views
- October 6, 2024
- 2
Dana-Farber Cancer Institute
CAR T-Cells in Multiple Myeloma in 2024
FEATURING
Adam Sperling
- 271 views
- July 2, 2024
- 4
Dana-Farber Cancer Institute
Updates on AL Amyloidosis Treatment: What’s New in 2024
FEATURING
Giada Bianchi
- 180 views
- July 2, 2024
Nebraska Oncology Society
Therapeutic Potential of Bispecific Antibodies and BiTEs in Treating MM
FEATURING
Al-Ola Abdallah
- 61 views
- July 10, 2024
Meral Beksaç
Post ASCO®/EHA 2024 Treatment of Transplant Ineligible Myeloma Patients
- 39 views
- July 22, 2024
Nebraska Oncology Society
Updates on Advances in the Treatment R/R Myeloma
FEATURING
Ravi Vij
- 78 views
- August 1, 2024
MyCancerHaven
Experts Discuss How They Plan to Use CAR-T in Myeloma After First Relapse
FEATURING
Ravi Vij,
Al-Ola Abdallah
- 72 views
- August 30, 2024
MyCancerHaven
Experts Discuss the Future of Personalized Therapy in Myeloma
FEATURING
Ravi Vij,
Kenneth Shain
- 25 views
- August 30, 2024
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 30 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Overview of R/R Multiple Myeloma and Data on Carfilzomib
FEATURING
Tulin Tuglular
- 17 views
- September 11, 2024
ecancer
Updates From the LINKER-MM1 Trial - Linvoseltamab in Patients With R/R MM
FEATURING
Suzanne Lentzsch
- 27 views
- September 18, 2024
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 294 views
- September 19, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Immunotherapy Sequencing in MM: Bispecifics Should be Used First
FEATURING
Semra Aydin
- 31 views
- September 25, 2024
COR2ED The Heart of Medical Education
Current Best Practices in Treating Early R/R MM
FEATURING
Joseph Mikhael
- 14 views
- October 1, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Navigating Len Maintenance in Myeloma
FEATURING
Metban Mastanzade
- 21 views
- October 8, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Overview of Carfilzomib Treatment in R/R MM
FEATURING
Mehmet Hilmi Dogu
- 5 views
- October 15, 2024
Indy Hematology Review
Multiple Myeloma: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 230 views
- April 18, 2024
- 2
Lucio Gordan
Impact of a Best Practices Program in Patients With R/R MM Receiving Selinexor
- 128 views
- April 8, 2024
- 1
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
FEATURING
Daniel Sherbenou
- 436 views
- April 11, 2024
- 1
MyCancerHaven
The Influence of PERSEUS and IsKia Trials on Frontline Therapy Choices in MM
FEATURING
Ravi Vij,
Thomas Martin
- 91 views
- May 13, 2024
- 2
Fredrik Schjesvold
IKEMA Trial Updated Analysis: Isa-Kd in Patients With R/R MM
- 48 views
- May 13, 2024
Yale Cancer Center
Frontline Treatment Strategies in MM: A Comprehensive Overview of Clinical Trials and Real-World Data
FEATURING
Terri Parker
- 118 views
- May 14, 2024
- 1
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of CAR-Ts in Earlier Lines
FEATURING
Doris Hansen
- 378 views
- April 15, 2024
- 2
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 912 views
- April 16, 2024
- 5
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
FEATURING
Kenneth Anderson
- 1,224 views
- April 16, 2024
- 5
Lucio Gordan
TAURUS Study: Chart Review of DRd vs. VRd in Transplant-Ineligible Patients With NDMM
- 202 views
- April 26, 2024
- 1
City of Hope
Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma
FEATURING
Murali Janakiram
- 288 views
- April 26, 2024
- 3
MyCancerHaven
Experts Discuss Novel Antibodies for the Management of Amyloidosis
FEATURING
Ravi Vij,
Suzanne Lentzsch
- 132 views
- May 7, 2024
- 1
Dickran Kazandjian
Overall Survival in Newly Diagnosed, Transplant-Ineligible MM: Results From MAIA
- 141 views
- August 9, 2024
ecancer
EHA 2024 Insights: DREAMM-8 Trial Summary - Belamaf + PomDex Vs. Bortezomib + PomDex in R/R MM
FEATURING
Meletios Dimopoulos
- 34 views
- July 24, 2024
Jill Corre
Dara-VTd & Dara Maintenance in Transplant-Eligible Newly Diagnosed MM: CASSIOPEIA Trial MRD Update
- 30 views
- October 14, 2024
ecancer
Isa-KRd in NDMM: Takeaways From the MIDAS & CONCEPT Studies
FEATURING
Philippe Moreau
- 8 views
- November 18, 2024
MyCancerHaven
Conversation With Cancer Experts: SC Dara + Len vs. Len for Post-Transplant Maintenance in NDMM - AURIGA Study
FEATURING
Ravi Vij,
Ashraf Badros
- 31 views
- November 27, 2024
Tisch Cancer Institute at Mount Sinai
Non Immune-Based Approaches for Advanced Myeloma
FEATURING
Gurbakhash Kaur
- 15 views
- November 21, 2024
MyCancerHaven
Conversation With Cancer Experts: Dara SC + VRd for Transplant-Ineligible or Deferred NDMM - Ph3 CEPHEUS Study
FEATURING
Ravi Vij,
Saad Usmani
- 19 views
- November 27, 2024
- 1
Scripps Health
AL Amyloidosis: Current and Emerging Treatments
FEATURING
David Oveisi
- 11 views
- November 4, 2024
Lisa Leypoldt
Isa-KRd in High-Risk NDMM: 4-Year Follow-Up From the GMMG-CONCEPT Trial
- 8 views
- November 22, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in MM: The Role of Immunotherapy
FEATURING
Adam D. Cohen
- 291 views
- March 1, 2024
- 4
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?
FEATURING
Ariel Grajales-Cruz
- 267 views
- March 4, 2024
- 6
ecancer
PERSEUS Trial Summary: Adding Daratumumab to VRd as a Frontline Therapy for Newly Diagnosed MM
FEATURING
Pieter Sonneveld
- 193 views
- March 5, 2024
- 2
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dyscrasias
- 117 views
- March 6, 2024
GRACE
The Future of Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 28 views
- March 6, 2024
GRACE
A Summary of Efficacy and Safety Data From Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 149 views
- March 6, 2024
- 1
GRACE
Choosing CAR T-Cell or Bispecifics After Standard Myeloma Therapy Exhaustion: Panel Discussion
- 26 views
- March 11, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Experimental Therapies for Relapsed Myeloma
FEATURING
Dan Vogl
- 40 views
- March 13, 2024
UChicago Medicine
Multiple Myeloma: CAR T-Cells and Bispecifics - A Case for Moving Them Early
FEATURING
Noopur Raje
- 257 views
- March 18, 2024
- 1
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
FEATURING
Richard Childs
- 756 views
- April 18, 2024
- 5
MyCancerHaven
Conversation With Cancer Experts: Cilta-cel for R/R MM - Real World Experience
FEATURING
Ravi Vij,
Surbhi Sidana
- 11 views
- December 2, 2024
Muhammad Abid
Infectious Complications in Pts Receiving CD19 vs. BCMA Targeted CAR-T Therapy
- 5 views
- December 10, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From CAR-PRISM Study
FEATURING
Omar Nadeem
- 1 view
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone in RRMM
FEATURING
Muhamed Baljevic
- 2 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L ASCT - KarMMa-2 Trial Follow-Up
FEATURING
Barry Paul
- 3 views
- December 17, 2024
Diagnostics & Biomarkers
University of Colorado Division of Hematology
Multiple Myeloma: Initial Workup, Diagnosis, and Risk Assessment
FEATURING
Alex Hirose
- 20 views
- October 16, 2024
Winship Cancer Institute - Emory University
AI in Multiple Myeloma: Recent Findings and Opportunities
FEATURING
Anant Madabhushi
- 97 views
- October 21, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 97 views
- June 20, 2024
Rush University Medical Center
High-Risk Myeloma: Updates in Defining and Managing
FEATURING
Jeffrey Zonder
- 133 views
- June 6, 2024
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
FEATURING
Kenneth Anderson
- 650 views
- July 1, 2024
- 5
Dana-Farber Cancer Institute
Multiple Myeloma 101: Diagnosis, Prognosis, and Risk
FEATURING
Paul Richardson
- 714 views
- July 2, 2024
- 5
ecancer
ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple Myeloma"
FEATURING
Xavier Leleu
- 78 views
- July 18, 2024
- 1
MyCancerHaven
Experts Discuss the Future of Personalized Therapy in Myeloma
FEATURING
Ravi Vij,
Kenneth Shain
- 25 views
- August 30, 2024
Jill Corre
A New Consensus for Classification of High-Risk Myeloma Based on Cytogenetic Abnormalities
- 207 views
- October 14, 2024
- 1
Wee Joo Chng
Other Factors for Identifying High-Risk Myeloma Patients Beyond Cytogenetics
- 25 views
- October 15, 2024
- 1
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma
FEATURING
Mary Kwok
- 426 views
- August 14, 2024
- 3
Scripps Health
Cardiac Amyloidosis: Who to Suspect and How to Treat?
FEATURING
Rajeev Mohan
- 474 views
- April 26, 2024
- 3
Houston Methodist
Musculoskeletal Pathology as an Early Warning Sign of Systemic Amyloidosis - 2024
FEATURING
Shari Liberman
- 32 views
- April 19, 2024
Springer Healthcare IME
Speed-Meet the Multidisciplinary Team: Cardiologist
FEATURING
Roberta Mussinelli
- 1 view
- December 4, 2024
ecancer
ASCO® 2024 Insights: "PERSEUS Trial - MRD Analysis of Dara + VRd in Transplant-Eligible NDMM"
FEATURING
Paula Rodríguez-Otero
- 64 views
- June 24, 2024
- 1
Springer Healthcare IME
Speed-Meet the Multidisciplinary Team: Hematologist
FEATURING
Paolo Milani
- 1 view
- December 4, 2024
Ola Landgren
A New System for Genomic Classification and Individualized Prognosis in NDMM
- 46 views
- March 5, 2024
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should Use a Response-Adapted Approach to Transplant
FEATURING
Kenneth Shain
- 232 views
- March 11, 2024
- 1
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
FEATURING
Noopur S. Raje
- 479 views
- March 15, 2024
- 1
Springer Healthcare IME
Chapter 2: Unmet Needs in Amyloidosis Diagnosis and Care - Vaishali Sanchorawala
FEATURING
Vaishali Sanchorawala
- 10 views
- December 5, 2024
Disease Overview
University of Colorado Division of Hematology
Multiple Myeloma: Initial Workup, Diagnosis, and Risk Assessment
FEATURING
Alex Hirose
- 20 views
- October 16, 2024
University of Colorado Division of Hematology
Multiple Myeloma: Disease Origins and Pathophysiology
FEATURING
Alex Hirose
- 30 views
- October 17, 2024
Dana-Farber Cancer Institute
Updates in the Management of SMM/MGUS and the Prevention of Progression
FEATURING
Yuxin Liu
- 92 views
- July 2, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of Smoldering Myeloma
FEATURING
Claudio Cerchione
- 63 views
- August 27, 2024
- 1
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 25 views
- October 7, 2024
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma
FEATURING
Mary Kwok
- 426 views
- August 14, 2024
- 3
Scripps Health
Cardiac Amyloidosis: Who to Suspect and How to Treat?
FEATURING
Rajeev Mohan
- 474 views
- April 26, 2024
- 3
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
Multiple Myeloma: Not as Simple as "CRAB" Anymore
FEATURING
Rahul Banerjee
- 507 views
- August 14, 2024
- 5
GRACE
Multiple Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'
FEATURING
Hamza Hashmi
- 34 views
- November 25, 2024
Springer Healthcare IME
Speed Meet Our Multidisciplinary Team - Christine Chiti
FEATURING
Christine Chiti
- December 4, 2024
Morie Gertz
"You Have AL-Amyloidosis": Counseling Newly Diagnosed Patients
- 217 views
- March 5, 2024
- 3
MyCancerHaven
Experts Discuss the Management of Monoclonal Gammopathy of Renal Significance
FEATURING
Ravi Vij,
Nelson Leung
- 167 views
- September 5, 2024
- 3
University of Colorado Division of Hematology
Multiple Myeloma: Oncologic Emergencies and How to Manage Them
FEATURING
Alex Hirose
- 20 views
- October 14, 2024
Case Studies
University of Colorado Division of Hematology
Multiple Myeloma: Initial Workup, Diagnosis, and Risk Assessment
FEATURING
Alex Hirose
- 20 views
- October 16, 2024
APP2APP Virtual Lectures, Inc
Anemia Case Discussions: Anemia Secondary to Hematologic Malignancy or Hemolysis
FEATURING
Dane Thomas
- 49 views
- July 12, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Case Discussion: Smoldering MM
FEATURING
Arda Bayar
- 14 views
- August 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
A Case of MM With Atypical Cutaneous Presentation Treated With Dara and CyBorD
FEATURING
Bengisu Ece Duman
- 10 views
- August 15, 2024
MyCancerHaven
Experts Discuss How They Manage MM in the Elderly
FEATURING
Ravi Vij,
Sascha Tuchman
- 37 views
- August 30, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Treatment Strategies for R/R Multiple Myeloma
FEATURING
Claudio Cerchione
- 30 views
- September 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Navigating Len Maintenance in Myeloma
FEATURING
Metban Mastanzade
- 21 views
- October 8, 2024
ecancer
Case-Based Discussion On Managing Newly Diagnosed Multiple Myeloma
FEATURING
Dibeyndu De
- 5 views
- November 18, 2024
Winship Cancer Institute - Emory University
Multiple Myeloma: Clinical Challenges for the Community Clinician
FEATURING
Nisha Joseph
- 257 views
- April 16, 2024
- 3
Moffitt Cancer Center
Optimal Timing of CAR-T in Myeloma: Case-Based Discussion
FEATURING
Ciara Freeman
- 31 views
- March 7, 2024
GRACE
Experts Discuss Their Approach to Auto-Transplant for Young Standard-Risk Myeloma Patients
- 15 views
- March 20, 2024
